A framework for advancing our understanding of cancer-associated fibroblasts
Open accessThe DOI matches its Crossref record; 178 of the 182 references it cites were found in a registry or an index; 114 of the 165 sources its claims cite were checked for support.
Abstract
Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating leukocytes. As such, they are a potential target for optimizing therapeutic strategies against cancer. However, many challenges are present in ongoing attempts to modulate CAFs for therapeutic benefit. These include limitations in our understanding of the origin of CAFs and heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions. On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus Statement our current knowledge and present a framework for advancing our understanding of this critical cell type within the tumour microenvironment.
Overview
CoChat Summary
## TL;DR
This Consensus Statement argues that cancer-associated fibroblasts (CAFs) are important, heterogeneous regulators of the tumour microenvironment and that better definitions, standardized assays, and metadata reporting are needed to make CAF-targeted therapy clinically useful. It emphasizes that CAFs can have both pro- and antitumorigenic effects, so future strategies should focus on CAF subtypes, interconvertibility, and function rather than blanket ablation.
## Key findings
- CAFs have diverse functions in tumour biology, including matrix deposition/remodeling, reciprocal signalling with cancer cells, crosstalk with leukocytes, effects on angiogenesis, tumour mechanics, drug access, and therapy response.
- The paper states that the consensus is that most CAFs likely arise from activation of local tissue-resident fibroblasts, but clear examples of alternative origins also exist.
- Evidence supports CAF heterogeneity and plasticity: recurrent CAF states include matrix-producing contractile myoCAFs and immunomodulatory iCAFs; in pancreatic cancer, proximal CAFs show high TGFβ-driven αSMA and distal CAFs express higher IL-6.
- The authors note that preclinical and correlative studies suggest improved treatment strategies may be possible by targeting CAFs, and say several clinical trials are underway; they also mention that a Hedgehog-pathway pancreatic cancer trial (NCT01130142) failed and reported decreased patient survival with gemcitabine.
## Methods
- Consensus Statement based on a Banbury Center meeting at Cold Spring Harbor Laboratory in March 2019, with an open discussion among participants and subsequent drafting, circulation, feedback, and refinement by the authors.
- The paper synthesizes findings from functional analyses in preclinical models, correlative analyses of patient material, mouse lineage-tracing studies, single-cell technologies, and clinical trial experience.
- Main analysis is qualitative and conceptual: it reviews CAF origin, activation, heterogeneity, function, and targeting, then proposes methodological recommendations for nomenclature, metadata, and assay standardization.
## Limitations
- The paper states that lack of precision around fibroblast-specific markers makes it difficult to define CAFs and to determine their exact origin.
- It states that longitudinal sampling of the same human lesion is rarely possible, making it hard to directly track CAF state conversion in patients.
- Evident from the text: much of the discussion is based on heterogeneous preclinical models, correlative patient studies, and expert consensus rather than a single systematic empirical study of CAFs (this is evident from the paper’s format and described approach).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
62 Valid · 6 Not valid · 23 Not checked · 7 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Contact between cancer cells and fibroblasts can promote the CAF phenotype in breast cancer through Notch signalling55”
§ A framework for advancing our understanding of cancer-associated fibroblasts > How are CAFs generated? The studies described in the previous section aimed to document which cells give rise to CAFs but do not provide a mechanism for their conversion. Given the prominent role fibroblasts play in coordinating the wound repair response in skin, it is plausible that key CAF traits correspond to the normal physiological role fibroblasts play. Well-established activating signals for fibroblasts include TGFβ family ligands and the lipid mediator lysophosphatidic acid52–54, which promote the activity of the SMAD transcription factors and serum response factor (SRF), respectively, and converge to drive expression of the activated fibroblast marker αSMA as well as increase the activity of the contractile cytoskeleton6 (Fig. 1). Contact between cancer cells and fibroblasts can promote the CAF phenotype in breast cancer through Notch signalling55; however, this mechanism is unlikely to be universal as loss of Notch signalling can promote CAF phenotypes in squamous cell carcinoma56. Various inflammatory modulators can promote CAF activation, with interleukin-1 (IL-1) acting through NF-κB and IL-6 acting primarily on signal transducer and activator of transcription (STAT) transcription factors57,58. Crosstalk and positive feedback involving Janus kinase (JAK)–STAT signalling, the contractile cytoskeleton and alterations in histone acetylation further promote CAF activation59,60. Physical changes in the ECM are also capable of activating CAFs53,61–64. In vitro studies have shown that fibroblast stretching, which may result from the hyperproliferation of transformed epithelial cells, can activate SRF-driven transcription and Yes-associated protein 1 (YAP1)–TEAD-driven transcription53,54,65,66. These transcription factors cooperate to drive the expression of a wide-range of genes associated with CAFs, including the genes encoding connective tissue growth factor (CTGF; also known as CCN2) and cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1)54. Furthermore, matricellular molecules, such as CTGF and CYR61, and the contractile cytoskeleton cooperate to increase tissue stiffness, which further drives SRF-dependent and YAP1-dependent transcriptional programmes, locking CAFs into a self-sustaining positive-feedback loop53. Physiological stress is also another factor contributing to stromagenesis. Heat shock factor 1 (HSF1), which responds in part to protein misfolding, is required for the generation of CAFs67,68. Physiological and genomic stresses can also trigger changes in fibroblasts. Double-stranded DNA breaks can promote the production of IL-6 and the TGFβ family ligand activin A69,70. In some cases, these triggers cause fibroblasts to enter a non-proliferative state termed ‘senescence’71, which is distinct from the phenotype of an aged fibroblast. There is clear overlap between the secretome of senescent fibroblasts and CAFs, with high levels of IL-6 production being common to both, and senescent fibroblasts have been found in the microenvironment of some tumours72. The non-proliferative nature of senescent cells makes it unlikely that they are a major contributor to the abundant stromal fibroblasts observed in desmoplastic tumours73. Nonetheless, it remains possible that CAFs and senescent fibroblasts share some transcriptional regulatory mechanisms74,75. Furthermore, even if senescent fibroblasts are a minor component of the tumour microenvironment, experimental analysis suggests that their elimination can have substantial consequences for disease relapse71. In addition to considering tumour cells as the direct source of cues that generate CAFs, signals from other cells within the tumour microenvironment may also instruct CAF function; for example, granulin produced by macrophages promotes the activation of a fibrotic environment in liver metastases76,77. Such mechanisms that do not directly depend on the presence of cancer may contribute to the protumorigenic environments found in inflammatory conditions that are linked to increased cancer risk. In addition, cancer therapies, including conventional chemotherapies, radiotherapy and targeted agents, can promote the generation of CAFs and modulate their functionality. These changes can aid the development of therapy resistance78–80 and contribute to undesirable side effects80. Being able to mitigate these events is another potential appeal of CAF-directed therapies.
What the sources say
- Supportedcites [55] Strell, C. et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J. Natl Cancer Inst. 111, 983–995 (2019). source
The Results abstract (p. 1, Results) states that the poor-prognosis-associated fibroblast phenotype is induced by DCIS cells 'in a cell contact-dependent manner', with epithelial Jagged1 and fibroblast Notch2 identified by loss-of-function (CRISPR/Cas9, siRNA) studies as the key juxtacrine signalling components; the Discussion (conclusion) calls this 'a novel, clinically relevant Notch-mediated mechanism of fibroblast activation in early stages of breast cancer development', with increased matrix-remodeling enzymes and TGF-beta ligands. This matches the claim's content: cancer-cell/fibroblast contact promoting an activated, adverse fibroblast (CAF-like) phenotype via Notch in breast cancer. The one qualifier to note is that the source demonstrates this in ductal carcinoma in situ (pre-invasive/early-stage breast cancer) and defines the phenotype as PDGFRalpha(low)/PDGFRbeta(high) rather than using the label 'CAF' for its own data. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While single-cell sequencing indicates common traits are preserved49–51, it will become increasingly pressing to define common and specific effects of CAFs.”
§ A framework for advancing our understanding of cancer-associated fibroblasts > What is the origin of CAFs? The lack of precision around fibroblast-specific markers poses a challenge when one is considering the origin of CAFs. When the markers of both normal tissue-resident fibroblasts and CAFs are ill-defined, it becomes very hard to propose hypotheses regarding the precise cell of origin of CAFs. To partially circumvent this problem, many studies have documented the changes in the fibroblastic component of carcinomas as they progress from hyperplasia, through adenoma or in situ lesion, to frank carcinoma in patients28. These studies using human tissue observe progressive changes in the fibroblastic stroma. In many cases, the initial apparent expansion of fibroblasts precedes the conversion to malignancy, and fibroblasts are often observed circumscribing early or premalignant lesions29,30. The gradual nature of the transitions observed has given rise to the view that the majority of stromal fibroblasts initially originate from local fibroblasts that experience some form of tissue dysfunction31,32. The expansion of stromal fibroblast number could result from proliferation, which has been experimentally observed in tumours, albeit with low frequency33. This process has been termed ‘stromagenesis’, with the implication that it proceeds alongside and is coupled to tumorigenesis34. Furthermore, experimental studies and observations of early lesions encircled by fibroblasts support the idea that the initial fibroblast response can be tumour suppressive35,36, with subsequent events in stromagenesis generating protumorigenic fibroblasts. It is currently difficult to explore this hypothesis in human tissue biopsy samples because longitudinal sampling of the same lesion through disease progression is rarely possible and, even when it is, the conversion between cell states cannot be directly tracked. To shed more light on the origin of CAFs, many researchers have turned to mouse models in which cells can be irreversibly labelled using transgenic techniques and well-characterized models of disease progression are available. These typically use tissue-restricted expression of the Cre recombinase in mice that also contain a reporter gene that becomes irreversibly active in cells that express Cre. Importantly, the active reporter will be inherited by all daughter cells and will continue to be expressed even if the Cre recombinase is not37. However, the lack of fibroblast-restricted markers causes problems when one is selecting a promoter to drive the expression of the Cre recombinase. This is exemplified by the divergent phenotypes observed in a colitis model of stromal knockout of Ikkb (inhibitor of nuclear factor-κB (NF-κB) kinase subunit-β) depending on whether a collagen type I α2 chain (Col1a2) or collagen type V α1 chain (Col5a1) Cre driver was used38,39. The most widely used fibroblast drivers and their caveats are detailed in the section entitled ‘Challenges and recommendations’. This approach can also be used to explore hypotheses including the conversion of adipocytes, pericytes, endothelial cells and bone marrow-derived mesenchymal stem cells (MSCs) into CAFs. The injection of bone marrow-derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40, with more recent studies supporting the MSC origin of PDGFRα– CAFs41. Adipocyte conversion into CAFs has been reported by several groups, although it does not appear to be a universally applicable phenomenon across different tumour types42–45. The reduction or absence of adipocytes in pathological tissue could also result from activated fibroblasts interfering with adipocyte differentiation46. In situations where adipocytes remain, they can engage in crosstalk with cancer cells and provide metabolic support independently of conversion into CAFs47. Evidence for pericyte conversion into CAFs is relatively sparse48, with tumorigenesis studies that targeted pericytes specifically not revealing large-scale differences in the tumour microenvironment. Ultimately, lineage tracing studies in mice remain hampered by the lack of highly specific Cre drivers for normal fibroblasts, difficulties of combining lineage tracing with genetically engineered models of mouse tumours that are also driven by Cre recombinase, the suboptimal nature of cell line-based tumour models and the lack of incentives to report negative data in such studies. Currently, it is also unclear whether individual CAF populations are preserved across tissues and species. While single-cell sequencing indicates common traits are preserved49–51, it will become increasingly pressing to define common and specific effects of CAFs. Techniques that provide spatial resolution, such as highly multiplexed antibody-based staining and multiplexed nucleic acid in situ hybridization, will also have a role to play in determining whether CAF subtype is strongly influenced by spatial location within the tumour. Together, these factors mean that definitive conclusions on the origin of CAFs are hard to reach. The consensus is that most CAFs likely result from the activation of local tissue-resident fibroblasts but that there are clear examples of alternative origins.
What the sources say
- Partly supportedcites [49] Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611–1624 e1624 (2017). sourceExperimental — accuracy not yet measured
The Results section reports that fibroblast expression states were reproducibly detected across HNSCC tumors. It also describes broad similarity between primary tumors and matched lymph-node metastases, though with differences in fibroblast subsets. These findings support common traits across the studied tumors and sites, but not preservation across species; no page numbers are available in our copy. (LLM, conf=0.87)
- Partly supportedcites [50] Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019). sourceExperimental — accuracy not yet measured
The paper’s discussion of homologous fibroblast subsets (indexed under Abstract; page unavailable) reports shared gene-expression profiles in human and mouse arthritic synovium, supporting preservation across species. It does not establish that those traits are preserved across different tissues; both datasets concern synovium. (LLM, conf=0.88)
- Partly supportedcites [51] Nayar, S. et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc. Natl Acad. Sci. USA 116, 13490–13497 (2019). sourceExperimental — accuracy not yet measured
The Discussion (page not available) describes immunofibroblast networks in humans and a mouse model as phenotypically and functionally similar to networks in secondary lymphoid organs. But the Results describe single-cell PCR in human salivary-gland fibroblasts, not single-cell sequencing demonstrating preserved traits across tissues and species; the Discussion also notes differences between murine and human fibroblasts. (LLM, conf=0.83)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Physical changes in the ECM are also capable of activating CAFs53,61–64.”
§ A framework for advancing our understanding of cancer-associated fibroblasts > How are CAFs generated? The studies described in the previous section aimed to document which cells give rise to CAFs but do not provide a mechanism for their conversion. Given the prominent role fibroblasts play in coordinating the wound repair response in skin, it is plausible that key CAF traits correspond to the normal physiological role fibroblasts play. Well-established activating signals for fibroblasts include TGFβ family ligands and the lipid mediator lysophosphatidic acid52–54, which promote the activity of the SMAD transcription factors and serum response factor (SRF), respectively, and converge to drive expression of the activated fibroblast marker αSMA as well as increase the activity of the contractile cytoskeleton6 (Fig. 1). Contact between cancer cells and fibroblasts can promote the CAF phenotype in breast cancer through Notch signalling55; however, this mechanism is unlikely to be universal as loss of Notch signalling can promote CAF phenotypes in squamous cell carcinoma56. Various inflammatory modulators can promote CAF activation, with interleukin-1 (IL-1) acting through NF-κB and IL-6 acting primarily on signal transducer and activator of transcription (STAT) transcription factors57,58. Crosstalk and positive feedback involving Janus kinase (JAK)–STAT signalling, the contractile cytoskeleton and alterations in histone acetylation further promote CAF activation59,60. Physical changes in the ECM are also capable of activating CAFs53,61–64. In vitro studies have shown that fibroblast stretching, which may result from the hyperproliferation of transformed epithelial cells, can activate SRF-driven transcription and Yes-associated protein 1 (YAP1)–TEAD-driven transcription53,54,65,66. These transcription factors cooperate to drive the expression of a wide-range of genes associated with CAFs, including the genes encoding connective tissue growth factor (CTGF; also known as CCN2) and cysteine-rich angiogenic inducer 61 (CYR61; also known as CCN1)54. Furthermore, matricellular molecules, such as CTGF and CYR61, and the contractile cytoskeleton cooperate to increase tissue stiffness, which further drives SRF-dependent and YAP1-dependent transcriptional programmes, locking CAFs into a self-sustaining positive-feedback loop53. Physiological stress is also another factor contributing to stromagenesis. Heat shock factor 1 (HSF1), which responds in part to protein misfolding, is required for the generation of CAFs67,68. Physiological and genomic stresses can also trigger changes in fibroblasts. Double-stranded DNA breaks can promote the production of IL-6 and the TGFβ family ligand activin A69,70. In some cases, these triggers cause fibroblasts to enter a non-proliferative state termed ‘senescence’71, which is distinct from the phenotype of an aged fibroblast. There is clear overlap between the secretome of senescent fibroblasts and CAFs, with high levels of IL-6 production being common to both, and senescent fibroblasts have been found in the microenvironment of some tumours72. The non-proliferative nature of senescent cells makes it unlikely that they are a major contributor to the abundant stromal fibroblasts observed in desmoplastic tumours73. Nonetheless, it remains possible that CAFs and senescent fibroblasts share some transcriptional regulatory mechanisms74,75. Furthermore, even if senescent fibroblasts are a minor component of the tumour microenvironment, experimental analysis suggests that their elimination can have substantial consequences for disease relapse71. In addition to considering tumour cells as the direct source of cues that generate CAFs, signals from other cells within the tumour microenvironment may also instruct CAF function; for example, granulin produced by macrophages promotes the activation of a fibrotic environment in liver metastases76,77. Such mechanisms that do not directly depend on the presence of cancer may contribute to the protumorigenic environments found in inflammatory conditions that are linked to increased cancer risk. In addition, cancer therapies, including conventional chemotherapies, radiotherapy and targeted agents, can promote the generation of CAFs and modulate their functionality. These changes can aid the development of therapy resistance78–80 and contribute to undesirable side effects80. Being able to mitigate these events is another potential appeal of CAF-directed therapies.
What the sources say
- Supportedcites [53] Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637–646 (2013). source
In Results, under ‘A positive feedback loop involving actomyosin contractility sustains YAP activation’ (page unavailable), blocking ECM stiffening reduced YAP activation in CAFs. The same section reports that increasing collagen-matrix stiffness drove YAP nuclear accumulation in normal fibroblasts. These findings support the claim that a physical change in the ECM can activate CAF-associated signalling. (LLM, conf=0.88)
- Supportedcites [61] Calvo, F. et al. Cdc42EP3/BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts. Cell Rep. 13, 2699–2714 (2015). source
The Discussion (p. 13) says that full activation of the CAF phenotype requires ECM stiffening alongside other activating changes. The paper therefore supports physical changes in the ECM as a contributor to CAF activation, not as a sufficient trigger on their own. (LLM, conf=0.90)
- Supportedcites [62] Amatangelo, M. D., Bassi, D. E., Klein-Szanto, A. J. & Cukierman, E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 167, 475–488 (2005). source
In the Discussion (page unavailable), normal fibroblasts replated in tumor-associated fibroblast–derived 3-D matrices developed desmoplastic morphology and expressed α-SMA and desmin. The paper also describes the matrices’ organized fibers and three-dimensional structure, supporting the claim that ECM changes can promote CAF-like activation. (LLM, conf=0.88)
- Supportedcites [63] Malik, R. et al. Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol. https://doi.org/10.1016/j.matbio.2018.11.001 (2018). source
The Introduction states that tissue stiffness regulates naïve-to-CAF activation. Stiffness is a physical property of the extracellular environment, so this supports the claim. No page number is provided in our copy. (LLM, conf=0.91)
- Partly supportedcites [64] Avery, D. et al. Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. Matrix Biol. 67, 90–106 (2018). sourceExperimental — accuracy not yet measured
The Results (§1.2.2; page unavailable) show that changing substrate stiffness shifts cultured fibroblasts between activated phenotypes. The Discussion (§1.3; page unavailable) suggests similar regulation likely occurs in tumors, but the study does not directly show that physical ECM changes activate cancer-associated fibroblasts in tumors. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The expansion of stromal fibroblast number could result from proliferation, which has been experimentally observed in tumours, albeit with low frequency33.”
§ A framework for advancing our understanding of cancer-associated fibroblasts > What is the origin of CAFs? The lack of precision around fibroblast-specific markers poses a challenge when one is considering the origin of CAFs. When the markers of both normal tissue-resident fibroblasts and CAFs are ill-defined, it becomes very hard to propose hypotheses regarding the precise cell of origin of CAFs. To partially circumvent this problem, many studies have documented the changes in the fibroblastic component of carcinomas as they progress from hyperplasia, through adenoma or in situ lesion, to frank carcinoma in patients28. These studies using human tissue observe progressive changes in the fibroblastic stroma. In many cases, the initial apparent expansion of fibroblasts precedes the conversion to malignancy, and fibroblasts are often observed circumscribing early or premalignant lesions29,30. The gradual nature of the transitions observed has given rise to the view that the majority of stromal fibroblasts initially originate from local fibroblasts that experience some form of tissue dysfunction31,32. The expansion of stromal fibroblast number could result from proliferation, which has been experimentally observed in tumours, albeit with low frequency33. This process has been termed ‘stromagenesis’, with the implication that it proceeds alongside and is coupled to tumorigenesis34. Furthermore, experimental studies and observations of early lesions encircled by fibroblasts support the idea that the initial fibroblast response can be tumour suppressive35,36, with subsequent events in stromagenesis generating protumorigenic fibroblasts. It is currently difficult to explore this hypothesis in human tissue biopsy samples because longitudinal sampling of the same lesion through disease progression is rarely possible and, even when it is, the conversion between cell states cannot be directly tracked. To shed more light on the origin of CAFs, many researchers have turned to mouse models in which cells can be irreversibly labelled using transgenic techniques and well-characterized models of disease progression are available. These typically use tissue-restricted expression of the Cre recombinase in mice that also contain a reporter gene that becomes irreversibly active in cells that express Cre. Importantly, the active reporter will be inherited by all daughter cells and will continue to be expressed even if the Cre recombinase is not37. However, the lack of fibroblast-restricted markers causes problems when one is selecting a promoter to drive the expression of the Cre recombinase. This is exemplified by the divergent phenotypes observed in a colitis model of stromal knockout of Ikkb (inhibitor of nuclear factor-κB (NF-κB) kinase subunit-β) depending on whether a collagen type I α2 chain (Col1a2) or collagen type V α1 chain (Col5a1) Cre driver was used38,39. The most widely used fibroblast drivers and their caveats are detailed in the section entitled ‘Challenges and recommendations’. This approach can also be used to explore hypotheses including the conversion of adipocytes, pericytes, endothelial cells and bone marrow-derived mesenchymal stem cells (MSCs) into CAFs. The injection of bone marrow-derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40, with more recent studies supporting the MSC origin of PDGFRα– CAFs41. Adipocyte conversion into CAFs has been reported by several groups, although it does not appear to be a universally applicable phenomenon across different tumour types42–45. The reduction or absence of adipocytes in pathological tissue could also result from activated fibroblasts interfering with adipocyte differentiation46. In situations where adipocytes remain, they can engage in crosstalk with cancer cells and provide metabolic support independently of conversion into CAFs47. Evidence for pericyte conversion into CAFs is relatively sparse48, with tumorigenesis studies that targeted pericytes specifically not revealing large-scale differences in the tumour microenvironment. Ultimately, lineage tracing studies in mice remain hampered by the lack of highly specific Cre drivers for normal fibroblasts, difficulties of combining lineage tracing with genetically engineered models of mouse tumours that are also driven by Cre recombinase, the suboptimal nature of cell line-based tumour models and the lack of incentives to report negative data in such studies. Currently, it is also unclear whether individual CAF populations are preserved across tissues and species. While single-cell sequencing indicates common traits are preserved49–51, it will become increasingly pressing to define common and specific effects of CAFs. Techniques that provide spatial resolution, such as highly multiplexed antibody-based staining and multiplexed nucleic acid in situ hybridization, will also have a role to play in determining whether CAF subtype is strongly influenced by spatial location within the tumour. Together, these factors mean that definitive conclusions on the origin of CAFs are hard to reach. The consensus is that most CAFs likely result from the activation of local tissue-resident fibroblasts but that there are clear examples of alternative origins.
What the sources say
- Supportedcites [33] Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017). source
In “CAFs coexist as two mutually exclusive and reversible subtypes” (page unavailable), the paper reports Ki67 coexpression in a fraction of inflammatory cancer-associated fibroblasts in KPC mouse tumours. That supports the claim that stromal fibroblast proliferation has been observed in tumours, albeit in only a fraction of the cells examined; the paper does not establish how much this contributes to stromal expansion. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Once cancer cells have disseminated, the de novo activation of fibroblasts at secondary sites favours the establishment of macrometastases via multiple mechanisms, including the production of matrix components such as tenascin and periostin that provide supporting signals to the cancer cells94,95.”
§ A framework for advancing our understanding of cancer-associated fibroblasts > The expanding range of CAF functions The functions of CAFs have been determined using a variety of strategies, ranging from reductionist cell culture experiments and mouse models to correlative associations in large patient cohorts. These approaches have revealed a diverse array of functions (Fig. 2). The relative ease of culturing CAFs and matched normal fibroblasts from patient material has greatly facilitated mechanistic delineation of CAF functions. CAFs are perhaps the most effective cell within the tumour microenvironment at depositing and remodelling the ECM. This depends on RHO and RAB GTPase-mediated control of integrin-mediated adhesions and the actomyosin cytoskeleton81–83 and is linked to downregulation of the transmembrane receptor CD36 (also known as platelet glycoprotein 4)84. CAFs also produce matrix-crosslinking enzymes and, together with force-mediated ECM remodelling (reviewed in detail85,86), these contribute to the increased stiffness of tumour tissue87–89. Although chemical crosslinks are not readily reversed, the production of matrix proteases allows the tumour matrix to be remodelled, and this can lead to the generation of permissive tracks that allow cancer cell invasion81. Contact-mediated Eph–ephrin signalling further influences cancer cell migration90. In addition to promoting local invasion, CAFs are able to boost metastasis in experimental models, and this correlated with their ability to remodel the ECM91–93. Once cancer cells have disseminated, the de novo activation of fibroblasts at secondary sites favours the establishment of macrometastases via multiple mechanisms, including the production of matrix components such as tenascin and periostin that provide supporting signals to the cancer cells94,95. These molecules boost WNT signalling94, which may link to the role of some fibroblasts in normal physiology in regulating stem cell niches that are rich in WNT ligands96,97. More recently, changes in ECM organization have been shown to influence the migration of infiltrating leukocytes, which has implications for the immune surveillance of tumours98. The alterations in matrix production and tumour mechanics that result in a large part from the action of CAFs have complex consequences for tumours. Increased tissue stiffness triggers prosurvival and proproliferation signalling in cancer cells99. Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105. Altered tissue mechanics are also likely to play a role in cancer development and premalignant disease; this is evidenced by the links between mammographic density and breast cancer incidence84. Targeting the interplay between CAFs and the mechanical properties of tumours for patient benefit is currently being explored (see Table 1).
What the sources say
- Partly supportedcites [94] Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85–89 (2011). sourceExperimental — accuracy not yet measured
The periostin half of the claim is well supported: our copy shows POSTN is produced by αSMA+/VIM+ stromal fibroblasts, is induced de novo in the lung stroma by infiltrating cancer cells, and that Postn−/− hosts show a decrease of macrometastase number and size to less than 10% of controls (p. 1, Fig. 3 legend p. 4). However, the tenascin part is not this paper's finding: the Discussion (p. 3) refers only to 'a recent report that implicated tumour-cell-derived tenascin C in breast cancer metastasis' (its refs 29,30), i.e. tenascin C there is tumour-cell-derived and credited to other work, not fibroblast-produced. The claim's framing of both matrix proteins as fibroblast products of this study therefore overstates the source. (LLM, conf=0.82)
- Partly supportedcites [95] Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867–874 (2011). sourceExperimental — accuracy not yet measured
The Results section reports activated fibroblasts in late metastatic foci and stromal tenascin C (TNC) in large lung nodules; the Discussion says TNC from infiltrating myofibroblasts accumulates as nodules expand (page numbers unavailable). This supports the tenascin component, but the paper does not show that de novo fibroblast activation causes macrometastases or that these fibroblasts produce periostin. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
42 more claims · 29 with their cited sources checked
Create a free account to see all 98 claims and to verify the 3 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast to noncancerous myo fi broblasts, CAFs do not revert back to their inactivated state and overexpress platelet-derived growth factor (PDGF) receptorβ , which in turn supports their own proliferation [41].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [41]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, CAFs increase the collagen density in tumor tissues, resulting in high matrix stiffness, cell proliferation, as well as hypoxia -through the procarcinogenic activity of TGFβ [41].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the various stromal cells within the TME, fibroblasts constitute the dominant cellular mass [27,28,29,30].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Kaur, A. et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532, 250–254 (2016).”
Cited work 10.1038/nature17392 · retracted 2025-10-29 · notice 10.1038/s41586-025-09719-z · this paper published 2020-01-24
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citationRetractedTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Self-citationMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Research works printed but not linked: 1
- Schneider C. A. et al. in Second Harmonic Generation Imaging (eds Pavone, F.S. & Campagnola, P.J.) 373–390 (Taylor & Francis, 2013).
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“Recently, the technology of multiplexed mRNA probes has been rapidly developed, and thus accurate quantitative methods for the detection of CAFs, in the long term, are promising [87].”
BackgroundInfluentialA single-cell and spatially resolved atlas of human breast cancers
Wu, S. Z., Al-Eryani, G., Roden, D. L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J. R., Bartonicek, N., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00911-1 · Cited by 1,775
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“In addition, as CAF activation and function are driven by signaling pathways including Hedgehog, NFκB, CXCR4, FGFR, or TGFβ, specific inhibitors of these pathways are also being studied in clinical trials (283).”
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Metadata
- Authors
- Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., Ramirez, D. C., Scherz-Shouval, R., Sherman, M. H., Stewart, S., Tlsty, T. D., Tuveson, D. A., Watt, F. M., Weaver, V., Weeraratna, A. T., & Werb, Z.
- Affiliations
- The Francis Crick Institute (GB)
- Fox Chase Cancer Center (US)
- Washington University in St. Louis (US)
- Cold Spring Harbor Laboratory (US)
- Salk Institute for Biological Studies (US)
- Goethe University Frankfurt (DE)
- Fred Hutch Cancer Center (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Harvard University (US)
- Northwell Health (US)
- NYU Langone Health (US)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- University of Pennsylvania (US)
- Oregon Health & Science University (US)
- University of California, San Francisco (US)
- Guy's Hospital (GB)
- Johns Hopkins Medicine (US)
- Corresponding author
- Sahai, Erik
- ORCID
- Sahai, Erik
- Astsaturov, Igor
- Cukierman, Edna
- DeNardo, David G.
- Egeblad, Mikala
- Evans, Ronald M.
- Fearon, Douglas
- Greten, Florian R.
- Hingorani, Sunil R.
- Hunter, Tony
- Hynes, Richard O.
- Jain, Rakesh K.
- Janowitz, Tobias
- Kimmelman, Alec C.
- Kolonin, Mikhail G.
- Maki, Robert G.
- Puré, Ellen
- Ramirez, Daniel C.
- Sherman, Mara H.
- Stewart, Sheila
- Tlsty, Thea D.
- Tuveson, David A.
- Watt, Fiona M.
- Weaver, Valerie
- Weeraratna, Ashani T.
- Werb, Zena
- Venue
- Nature Reviews Cancer
- Published
- 2020-01-24
- Volume
- 20
- Issue
- 3
- Pages
- 174-186
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC7046529
- OpenAlex
- W3003058300
- Cited by
- 3,863
- References
- 182
- Citations by year
- 2026: 554 · 2025: 626 · 2024: 686 · 2023: 652 · 2022: 647 · 2021: 498 · 2020: 193
- FWCI
- 53.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature reviews. Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- The Francis Crick Institute (cc-by)
- Funders
- U.S. Department of Defense (W81XWH1410240, W81XWH-16, DE-AC02-05CH11231, W81XWH, W81XWH‐14, U01CA210240)
- Howard Hughes Medical Institute (DE-AC02-05CH11231, W81XWH-14-1-0240)
- March of Dimes Foundation
- V Foundation for Cancer Research (P01CA117969)
- National Foundation for Cancer Research (R35-CA197743, R01-CA208205)
- Pancreatic Cancer Action Network
- Advanced Medical Research Foundation (R35-CA197743, R01-CA208205)
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Lustgarten Foundation (U01CA224013, SU2C-AACR-DT-20-16, 1R01CA188134, P20CA192996, U01CA210240, 5P50CA101955, 5P30CA45508, 1R01CA190092)
- Wellcome Trust (Z/17/Z, 206439, FC001144, 206439/Z/17/Z)
- Francis Crick Institute (10144, FC001144)
- Thompson Family Foundation
- Northwell Health
- Greenfield Foundation
- Sarcoma Alliance for Research through Collaboration
- Cancer Research UK (12905, 19258, SU2C-AACR-DT-20-16, FC001144, A19258, C219/A23522)
- Deutsche Forschungsgemeinschaft (DE-AC02-05CH11231, Gr1916/11-1, FOR 2438)
- Israel Science Foundation (401/17, 1384/1)
- National Institutes of Health (DE-AC02–05CH11231, U01 CA224173, W81XWH, project 2, 17-85-HING, CA-06927, PO1 CA107584, 5P30CA45508, P30CA045508, 5p30ca045508-35, W81XWH-14-1-0240)
- Stand Up To Cancer (SU2C-AACR-DT-20-16)
- Pfizer Pharmaceuticals
- Ludwig Center at Harvard
- Medical Research Council (401/17, FC001144, DE-AC02-05CH11231)
- Engineering and Physical Sciences Research Council (DE-AC02-05CH11231)
- Biotechnology and Biological Sciences Research Council
- National Cancer Institute (CA231252, U01CA224193, P20CA192996, U01CA199315, CA130919, R01CA207935, P01CA114046, R01CA244938, CA64872, P50CA101955, R21CA231252, R01CA188134, U10CA180944, PO1 CA107584, R01CA188430, R01CA130919, 17-85-HING, U01CA224173, CA199315, R21CA216745, P50CA196510, U01CA224013, U01CA224348, P20CA192994, R01CA174746, CA107584, 5P30CA45508, P01CA217805, R01CA188048, CA197743, CA143803, P30-CA045508, U54CA143803, DE-AC02-05CH11231, R35CA232124, R01CA232256, P01CA107584, R01CA177670, R35CA197743, R01CA203890, R01CA208205, U2CCA223303, R01CA157490, R01CA223483, CA 59831, R01CA217206, P30CA006927, R01CA161112, P30CA014195, P01CA117969, U01CA210240, P30CA010815, P30CA006973, CA06927, R01CA190092)
- National Institute of General Medical Sciences (R01GM095567)
- Lawrence Berkeley National Laboratory (AC02‐05CH11231, DE-AC02-05CH11231, 05CH11231)
- H2020 European Research Council (754320)
- U.S. Army Medical Research Acquisition Activity
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- cancer-associated fibroblasts, tumor microenvironment, extracellular matrix remodeling, CAF heterogeneity, CAF origin
- MeSH terms
- Cell Plasticity, Cancer-Associated Fibroblasts, Animals, Clinical Trials as Topic, Disease Susceptibility, Humans, Neoplasms, Signal Transduction, Biomarkers, Treatment Outcome, Stromal Cells, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A framework for advancing our understanding of cancer-associated fibroblasts. https://app.cochat.ai/papers/10.1038/s41568-019-0238-1
- The paper
- Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., . . . Werb, Z. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer. https://doi.org/10.1038/s41568-019-0238-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.